1. Home
  2. ARCB vs BEAM Comparison

ARCB vs BEAM Comparison

Compare ARCB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARCB
  • BEAM
  • Stock Information
  • Founded
  • ARCB 1923
  • BEAM 2017
  • Country
  • ARCB United States
  • BEAM United States
  • Employees
  • ARCB N/A
  • BEAM N/A
  • Industry
  • ARCB Trucking Freight/Courier Services
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ARCB Industrials
  • BEAM Health Care
  • Exchange
  • ARCB Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • ARCB 1.6B
  • BEAM 1.6B
  • IPO Year
  • ARCB N/A
  • BEAM 2020
  • Fundamental
  • Price
  • ARCB $68.78
  • BEAM $16.76
  • Analyst Decision
  • ARCB Buy
  • BEAM Strong Buy
  • Analyst Count
  • ARCB 13
  • BEAM 11
  • Target Price
  • ARCB $92.92
  • BEAM $48.90
  • AVG Volume (30 Days)
  • ARCB 295.4K
  • BEAM 1.8M
  • Earning Date
  • ARCB 08-01-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • ARCB 0.70%
  • BEAM N/A
  • EPS Growth
  • ARCB 50.16
  • BEAM N/A
  • EPS
  • ARCB 7.55
  • BEAM N/A
  • Revenue
  • ARCB $4,109,676,999.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • ARCB $0.24
  • BEAM N/A
  • Revenue Next Year
  • ARCB $6.18
  • BEAM $8.82
  • P/E Ratio
  • ARCB $9.05
  • BEAM N/A
  • Revenue Growth
  • ARCB N/A
  • BEAM N/A
  • 52 Week Low
  • ARCB $55.19
  • BEAM $13.53
  • 52 Week High
  • ARCB $129.83
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • ARCB 56.53
  • BEAM 44.29
  • Support Level
  • ARCB $67.39
  • BEAM $16.18
  • Resistance Level
  • ARCB $69.83
  • BEAM $18.33
  • Average True Range (ATR)
  • ARCB 2.67
  • BEAM 1.10
  • MACD
  • ARCB 0.30
  • BEAM 0.00
  • Stochastic Oscillator
  • ARCB 71.39
  • BEAM 28.65

About ARCB ArcBest Corporation

ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: